s0112225
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.500
- MYC_TARGETS_V1+0.400
- E2F_TARGETS+0.300
- G2M_CHECKPOINT+0.300
- OXIDATIVE_PHOSPHORYLATION+0.200
- DNA_REPAIR+0.100
- SPERMATOGENESIS+0.100
- WNT_BETA_CATENIN_SIGNALING+0.100
- HEDGEHOG_SIGNALING+0.000
- KRAS_SIGNALING_DN+0.000
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.600
- IL6_JAK_STAT3_SIGNALING-0.500
- ALLOGRAFT_REJECTION-0.400
- APICAL_SURFACE-0.400
- COAGULATION-0.400
- COMPLEMENT-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- HYPOXIA-0.400
- IL2_STAT5_SIGNALING-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_M86ECPHK | Embryonal tumors | — | 0.955 |
| 2 | C3N-02283 | — | cohortMD1 | 0.954 |
| 3 | SRR5088911 | — | — | 0.949 |
| 4 | TCGA-QK-A8Z7-01A-11R-A39I-07 | — | — | 0.949 |
| 5 | BS_V9HVBBDW | medulloblastoma | — | 0.948 |
| 6 | BS_YEB88D32 | medulloblastoma | — | 0.942 |
| 7 | BS_9PB3XH5D | medulloblastoma | — | 0.942 |
| 8 | BS_ZXYDSBM9 | medulloblastoma | — | 0.941 |
| 9 | BS_Y8D1F5WW | medulloblastoma | — | 0.941 |
| 10 | BS_GE2RVZE6 | medulloblastoma | — | 0.939 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |